Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -7.05% | -8.25% | 2.73% | 14.79% | -20.25% |
| Total Depreciation and Amortization | -332.75% | 16.84% | -10.18% | -0.69% | -1.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.94% | 10.05% | 666.28% | -85.69% | -9.80% |
| Change in Net Operating Assets | -65.22% | 471.99% | 48.39% | -370.30% | 232.72% |
| Cash from Operations | -41.56% | 35.17% | 19.71% | -15.17% | -12.93% |
| Capital Expenditure | -31.10% | 18.85% | -122.60% | 3.80% | -8.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 81.77% | -5.63% | 122.91% | -699.13% | -26.89% |
| Cash from Investing | 83.87% | -4.99% | 121.75% | -720.40% | -27.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 65.34% | -- | -- | -- | -- |
| Issuance of Common Stock | -30.00% | -12.14% | -98.65% | 10,532.84% | 88.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | 77.54% | -374.70% | -98.65% | 10,532.84% | 88.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 428.45% | 13.13% | 121.20% | -218.26% | -230.35% |
